IL105220A0 - Cyclohexanylidene compounds and pharmaceutical compositions containing them - Google Patents

Cyclohexanylidene compounds and pharmaceutical compositions containing them

Info

Publication number
IL105220A0
IL105220A0 IL10522093A IL10522093A IL105220A0 IL 105220 A0 IL105220 A0 IL 105220A0 IL 10522093 A IL10522093 A IL 10522093A IL 10522093 A IL10522093 A IL 10522093A IL 105220 A0 IL105220 A0 IL 105220A0
Authority
IL
Israel
Prior art keywords
cyclohexanylidene
compounds
pharmaceutical compositions
compositions containing
pharmaceutical
Prior art date
Application number
IL10522093A
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of IL105220A0 publication Critical patent/IL105220A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/45Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/46Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of non-condensed rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/26Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of rings other than six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/64Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups singly-bound to oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00Ethers; Compounds having groups, groups or groups
    • C07C43/02Ethers
    • C07C43/20Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
IL10522093A 1992-04-02 1993-03-30 Cyclohexanylidene compounds and pharmaceutical compositions containing them IL105220A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86211192A 1992-04-02 1992-04-02
US96876192A 1992-10-30 1992-10-30
PCT/US1993/002516 WO1993019751A1 (en) 1992-04-02 1993-03-05 Compounds useful for treating inflammatory diseases and inhibiting production of tumor necrosis factor

Publications (1)

Publication Number Publication Date
IL105220A0 true IL105220A0 (en) 1994-08-26

Family

ID=27127668

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10522093A IL105220A0 (en) 1992-04-02 1993-03-30 Cyclohexanylidene compounds and pharmaceutical compositions containing them

Country Status (10)

Country Link
US (1) US5605923A (en:Method)
EP (1) EP0636026B1 (en:Method)
JP (1) JP3251587B2 (en:Method)
CN (1) CN1094031A (en:Method)
AU (1) AU3924993A (en:Method)
DE (1) DE69331265T2 (en:Method)
IL (1) IL105220A0 (en:Method)
MA (1) MA22922A1 (en:Method)
MX (1) MX9301942A (en:Method)
WO (1) WO1993019751A1 (en:Method)

Families Citing this family (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE240290T1 (de) * 1992-04-02 2003-05-15 Smithkline Beecham Corp Verbindungen verwendbar für die behandlung von allergien und entzündungskrankheiten
WO1995000139A1 (en) * 1993-06-18 1995-01-05 Smithkline Beecham Corporation Compounds
WO1995009627A1 (en) * 1993-10-01 1995-04-13 Smithkline Beecham Corporation Compounds, compositions and treatment of allergies and inflammation therewith
US6013827A (en) * 1994-03-11 2000-01-11 Smithkline Beecham Corporation Compounds
GB9404706D0 (en) * 1994-03-11 1994-04-27 Smithkline Beecham Corp Compounds
US5998428A (en) * 1995-05-31 1999-12-07 Smithkline Beecham Corporation Compounds and methods for treating PDE IV-related diseases
ZA9510826B (en) * 1994-12-23 1996-06-20 Smithkline Beecham Corp 3,3-(disubstituted)cyclohexan-1-ol monomers and related compounds
ATE306260T1 (de) * 1994-12-23 2005-10-15 Smithkline Beecham Corp Monomere der 4,4-(disubstituierten)cyclohexan-1- ole und verwandte verbindungen
JPH10511395A (ja) * 1994-12-23 1998-11-04 スミスクライン・ビーチャム・コーポレイション 1,3,3−(三置換)シクロヘキサン単量体および関連する化合物
JPH10511390A (ja) * 1994-12-23 1998-11-04 スミスクライン・ビーチャム・コーポレイション 1,4,4−(三置換)シクロヘクス−1−エンダイマーおよび関連化合物
WO1996020157A1 (en) * 1994-12-23 1996-07-04 Smithkline Beecham Corporation 3,3-(disubstituted)cyclohexan-1-ol dimers and related compounds
US5777176A (en) * 1994-12-23 1998-07-07 Smithkline Beecham Corporation 4,4-(disubstituted)cyclohexan-1-ol dimers and related compounds
DE59610077D1 (de) * 1995-05-18 2003-02-27 Altana Pharma Ag Phenyldihydrobenzofurane
CA2221351A1 (en) * 1995-05-18 1996-11-21 Byk Gulden Lomberg Chemische Fabrik Gmbh Cyclohexyl dihydrobenzofuranes
AR004471A1 (es) * 1995-05-31 1998-12-16 Smithkline Beecham Corp Compuestos de ciclohexan-1-ol-4,4-disustituidos, utiles en el tratamiento de enfermedades alergicas e inflamatorias y composiciones farmaceuticas que lascontienen
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US5891883A (en) * 1995-12-21 1999-04-06 Smithkline Beecham Corporation 4,4-(disubstituted)cyclohexan-1-ols monomers and related compounds
US6294573B1 (en) 1997-08-06 2001-09-25 Abbott Laboratories Reverse hydroxamate inhibitors of matrix metalloproteinases
US6235786B1 (en) 1997-08-06 2001-05-22 Abbott Laboratories Reverse hydroxamate inhibitors of matrix metalloproteinases
US6288261B1 (en) 1998-12-18 2001-09-11 Abbott Laboratories Inhibitors of matrix metalloproteinases
DZ3019A1 (fr) * 1999-03-01 2005-05-20 Smithkline Beecham Corp Utilisation d'un inhibiteur de pde4 dans la préparation d'un médicament contre la copd.
US20020077276A1 (en) * 1999-04-27 2002-06-20 Fredeking Terry M. Compositions and methods for treating hemorrhagic virus infections and other disorders
US20040220424A1 (en) * 1999-08-06 2004-11-04 Smithkline Beecham Corporation Process for preparing acids via alpha-chloroepoxy esters
UY26268A1 (es) * 1999-08-06 2001-01-31 Smithkline Beecham Corp Procedimiento para preparar acidos a traves de alfa-cloroep xi- esteres ley 17164 art 127
AU777012B2 (en) 1999-08-21 2004-09-30 Takeda Gmbh Synergistic combination of PDE inhibitors and beta 2 adrenoceptor agonist
US6572794B1 (en) 2000-07-24 2003-06-03 Essilor International Compagnie Generale D'optique Method of manufacturing a photochromic molded article
FR2816950B1 (fr) 2000-11-17 2003-02-14 Essilor Int Procede d'obtention d'un latex photochromique
FR2819258B1 (fr) 2001-01-11 2003-04-11 Essilor Int Procede d'obtention d'un latex photochromique stabilise, latex obtenu et application a l'optique ophtalmique
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
TWI354561B (en) 2002-07-19 2011-12-21 Abbott Lab S A Pharmaceutical compositions and uses for treatment
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2004087211A2 (en) 2003-04-01 2004-10-14 Applied Research Systems Ars Holding N.V. Inhibitors of phosphodiesterases in infertility
US20090274676A1 (en) * 2003-07-31 2009-11-05 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050085430A1 (en) * 2003-07-31 2005-04-21 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026883A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050187278A1 (en) * 2003-08-28 2005-08-25 Pharmacia Corporation Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
US20070078120A1 (en) * 2003-10-21 2007-04-05 Hitoshi Ban Novel piperidine derivative
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
TWI556829B (zh) 2004-04-09 2016-11-11 艾伯維生物技術有限責任公司 用於治療TNFα相關失調症之多重可變劑量療法
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
GB0414054D0 (en) 2004-06-23 2004-07-28 Owen Mumford Ltd Improvements relating to automatic injection devices
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
NZ627177A (en) 2005-05-16 2016-02-26 Abbvie Biotechnology Ltd Use of tnf inhibitor for treatment of erosive polyarthritis
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
CA2625664C (en) 2005-10-21 2016-01-05 Novartis Ag Human antibodies against il13 and therapeutic uses
RS53055B (sr) 2005-11-01 2014-04-30 Abbvie Biotechnology Ltd Postupci za određivanje efikasnosti adalimumaba kod ispitanika koji imaju ankilozirajući spondilitis koristeći ctx-ii i mmp3 kao biomarkere
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
NZ571479A (en) 2006-04-05 2012-10-26 Abbott Biotech Ltd Antibody purification
US9624295B2 (en) 2006-04-10 2017-04-18 Abbvie Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
CA2564435A1 (en) 2006-04-10 2007-10-10 Abbott Biotechnology Ltd. Methods for monitoring and treating intestinal disorders
EP2703010A3 (en) 2006-04-10 2014-08-06 AbbVie Biotechnology Ltd Uses and compositions for treatment of rheumatoid arthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
HRP20120494T1 (hr) 2006-04-21 2012-08-31 Novartis Ag Derivati purina za uporabu kao agonista adenozin a2a receptora
KR101396797B1 (ko) 2006-06-30 2014-05-26 애브비 바이오테크놀로지 리미티드 자동 주사 장치
CN101516885A (zh) 2006-09-29 2009-08-26 诺瓦提斯公司 作为pi3k脂质激酶抑制剂的吡唑并嘧啶类化合物
RU2009120389A (ru) 2006-10-30 2010-12-10 Новартис АГ (CH) Гетероциклические соединения в качестве противовоспалительных агентов
NZ577939A (en) 2007-01-10 2011-03-31 Irm Llc Compounds and compositions as channel activating protease inhibitors
US20090182035A1 (en) * 2007-04-11 2009-07-16 Alcon Research, Ltd. Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
MX2009010946A (es) * 2007-04-11 2009-10-29 Alcon Res Ltd Uso de un inhibidor del factor de necrosis tumoral alfa mas una antihistamina para tratar rinitis alergica y conjuntivitis alergica.
KR20100005730A (ko) 2007-05-07 2010-01-15 노파르티스 아게 유기 화합물
MX2009013293A (es) 2007-06-04 2010-02-15 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US8999337B2 (en) 2007-06-11 2015-04-07 Abbvie Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
EA017919B1 (ru) 2007-12-10 2013-04-30 Новартис Аг Производные пиразин-2-карбоксамида для лечения заболеваний, которые поддаются лечению путем блокирования эпителиальных натриевых каналов
PT2231642E (pt) 2008-01-11 2014-03-12 Novartis Ag Pirimidinas como inibidores de quinase
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
US8236808B2 (en) 2008-06-10 2012-08-07 Novartis Ag Pyrazine derivatives as ENAC blockers
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010088335A1 (en) 2009-01-29 2010-08-05 Novartis Ag Substituted benzimidazoles for the treatment of astrocytomas
EP2424594A4 (en) 2009-04-29 2014-12-24 Abbvie Biotechnology Ltd AUTOMATIC INJECTION DEVICE
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EP2464649A1 (en) 2009-08-12 2012-06-20 Novartis AG Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
DK2467141T3 (en) 2009-08-17 2019-02-18 Intellikine Llc HETEROCYCLIC COMPOUNDS AND APPLICATIONS THEREOF
BR112012008061A2 (pt) 2009-08-20 2016-03-01 Novartis Ag compostos de oxima heterocíclica
AU2010300421B2 (en) * 2009-10-01 2014-01-23 Alcon Research, Ltd. Olopatadine compositions and uses thereof
WO2011050325A1 (en) 2009-10-22 2011-04-28 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
CA2781725A1 (en) 2009-12-16 2011-06-23 Philip Bosch Methods of treating interstitial cystitis
MX2012008985A (es) 2010-02-02 2012-09-07 Abbott Biotech Ltd Metodos y composiciones para predecir la capacidad de respuesta al tratamiento con el inhibidor de tnf-alfa.
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
CA3033018C (en) 2010-04-21 2022-01-25 Abbvie Biotechnology Ltd. Wearable automatic injection device for controlled delivery of therapeutic agents
US20110287018A1 (en) 2010-05-19 2011-11-24 Philip Bosch Methods of Treating Interstitial Cystitis
US8747854B2 (en) 2010-06-03 2014-06-10 Abbvie Biotechnology Ltd. Methods of treating moderate to severe hidradenitis suppurativa with anti-TNF-alpha antibodies
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
US9265887B2 (en) 2011-01-24 2016-02-23 Abbvie Biotechnology Ltd. Automatic injection devices having overmolded gripping surfaces
JP2014505088A (ja) 2011-02-10 2014-02-27 ノバルティス アーゲー C−METチロシンキナーゼ阻害剤としての[1,2,4]トリアゾロ[4,3−b]ピリダジン化合物
EP2678016B1 (en) 2011-02-23 2016-08-10 Intellikine, LLC Heterocyclic compounds and uses thereof
PH12013501758A1 (en) 2011-02-25 2013-10-14 Irm Llc Pyrazolo [1,5-a] pyridines as trk inhibitors
ES2664873T3 (es) 2011-03-01 2018-04-23 Synergy Pharmaceuticals Inc. Proceso de preparación de agonistas de guanilato ciclasa C
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
MX339302B (es) 2011-09-15 2016-05-19 Novartis Ag 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina.
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
ES2558457T3 (es) 2011-09-16 2016-02-04 Novartis Ag Compuestos heterocíclicos para el tratamiento de fibrosis quística
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
EP2755652B1 (en) 2011-09-16 2021-06-02 Novartis AG N-substituted heterocyclyl carboxamides
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
JP6130391B2 (ja) 2011-11-23 2017-05-17 インテリカイン, エルエルシー Mtor阻害剤を使用する強化された治療レジメン
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
EP3964513A1 (en) 2012-04-03 2022-03-09 Novartis AG Combination products with tyrosine kinase inhibitors and their use
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
EP3718557A3 (en) 2013-02-25 2020-10-21 Bausch Health Ireland Limited Guanylate cyclase receptor agonist sp-333 for use in colonic cleansing
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
JP2016512835A (ja) 2013-03-15 2016-05-09 インテリカイン, エルエルシー キナーゼ阻害剤の組み合わせ及びそれらの使用
HK1220696A1 (zh) 2013-03-15 2017-05-12 Bausch Health Ireland Limited 鸟苷酸环化酶激动剂及其用途
KR102272746B1 (ko) 2013-06-05 2021-07-08 보슈 헬스 아일랜드 리미티드 구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법
AU2014305843B2 (en) 2013-08-09 2019-08-29 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
JP6433509B2 (ja) 2014-04-24 2018-12-05 ノバルティス アーゲー ホスファチジルイノシトール3−キナーゼ阻害薬としてのアミノピラジン誘導体
BR112016023967A2 (pt) 2014-04-24 2017-08-15 Novartis Ag derivados de pirazina como inibidores de fosfatidilinositol 3-cinase
EP3134396B1 (en) 2014-04-24 2019-09-18 Novartis AG Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
US20170183376A1 (en) 2014-06-24 2017-06-29 Insight Biopharmaceuticals Ltd. Methods of purifying antibodies
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
CA2954862A1 (en) 2014-07-31 2016-02-04 Novartis Ag Combination therapy
WO2016160976A2 (en) 2015-03-30 2016-10-06 Abbvie Inc. Monovalent tnf binding proteins
EP3078675A1 (en) 2015-04-10 2016-10-12 Ares Trading S.A. Induction dosing regimen for the treatment of tnf alpha mediated disorders
EP3257866A1 (en) 2016-06-17 2017-12-20 Academisch Medisch Centrum Modified anti-tnf antibody and use thereof in the treatment of ibd
JOP20190162A1 (ar) 2016-12-30 2019-06-27 Biocad Joint Stock Co تركيبة صيدلانية مائية من جسم مضاد لـ tnf? أحادي النسيلة معاود الارتباط الجيني
WO2020048828A1 (en) 2018-09-03 2020-03-12 Bayer Pharma Aktiengesellschaft 5-heteroaryl-3,9-diazaspiro[5.5]undecane compounds
WO2020048827A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 1, 3, 9-triazaspiro[5.5] undecan-2-one compounds
US20200368223A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Methods for inhibiting phosphate transport
EP3980121A1 (en) 2019-06-10 2022-04-13 Novartis AG Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis
AU2020338971B2 (en) 2019-08-28 2023-11-23 Novartis Ag Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
EP4515325A1 (en) 2022-04-26 2025-03-05 Essilor International Photochromic optical article having a mirror coating

Also Published As

Publication number Publication date
US5605923A (en) 1997-02-25
EP0636026A4 (en:Method) 1995-02-22
CN1094031A (zh) 1994-10-26
JPH07508263A (ja) 1995-09-14
DE69331265T2 (de) 2002-08-08
EP0636026A1 (en) 1995-02-01
EP0636026B1 (en) 2001-12-05
JP3251587B2 (ja) 2002-01-28
WO1993019751A1 (en) 1993-10-14
AU3924993A (en) 1993-11-08
DE69331265D1 (de) 2002-01-17
MX9301942A (es) 1994-08-31
MA22922A1 (fr) 1994-04-01

Similar Documents

Publication Publication Date Title
IL105220A0 (en) Cyclohexanylidene compounds and pharmaceutical compositions containing them
IL105218A0 (en) Hexanones and pharmaceutical compositions containing them
IL105223A0 (en) Cyclohexane-ylidenes and pharmaceutical compositions containing them
IL104824A0 (en) Heterobicyclic compounds and pharmaceutical compositions containing them
NZ244766A (en) Bi-aromatic compounds and pharmaceutical compositions
GB9209078D0 (en) Pharmaceutical compositions
GB9319500D0 (en) Pharmaceutical composition
IL106098A0 (en) Heteroarylnaphthalenes and pharmaceutical compositions containing them
IL105222A0 (en) Cyclohex-1-ene compounds and pharmaceutical compositions containing them
AU5100393A (en) Diindolo compounds and pharmaceutical compositions containing them
IL108073A0 (en) Substituted 6-azaandrostenones their preparation and pharmaceutical compositions containing them
GB2272375B (en) Pharmaceutical composition
EP0587047A3 (en) Gestagenes containing pharmaceutical composition
IL107611A0 (en) Steroid compounds and pharmaceutical compositions containing them
GB9209874D0 (en) Pharmaceutical compositions
GB9221707D0 (en) Pharmaceutical composition
ZA94155B (en) Pharmaceutical composition
ZA935078B (en) Pharmaceutical composition
IL106352A0 (en) Pyridoindolo-benzodiazepines and pharmaceutical compositions containing them
IL103132A0 (en) Digitalis-like compounds and pharmaceutical compositions containing them
ZA924061B (en) Pharmaceutical composition
ZA935931B (en) Pharmaceutical composition
GB9211276D0 (en) Pharmaceutical compositions
ZA931984B (en) Pharmaceutical composition
IL103936A (en) Trans-substituted-2H-1-benzopyranol derivatives and pharmaceutical compositions containing them